FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
Drug and Formulary Management
Because of the impact of Hurricanes Maria and Irma on Puerto Rico’s infrastructure and drug manufacturing, hospitals face an ongoing shortage of IV fluids manufactured there.
While there are rumors that President Barack Obama could use his executive authority to regulate drug pricing, analysts say that is not likely. Experts also say that the presidential candidates’ plans to reform skyrocketing drug prices won’t work.
Deaths from drug overdoses are the leading cause of injury death in the United States, ahead of deaths linked to motor vehicles and firearms, according to the new 2015 National Drug Threat Assessment (NDTA), released by the Drug Enforcement Administration.
There’s no hiding that hospital pharmacies have long been considered cost centers for healthcare systems. That positioning has been accentuated over the past 5 years, as the healthcare industry has seen a steady increase in high-cost, brand-name specialty medications that range from hundreds to thousands, sometimes tens of thousands, of dollars per dose. Nearly every hospital, however, has untapped opportunities to substantially improve efficiencies and improve costs. One important factor is improving how these hospitals use generic medications.
Specialty drug spending per user has increased considerably in recent years, but still represents a small portion of overall drug spending per beneficiary, according to a study published recently in Health Affairs.
Zykadia (ceritinib) is a tyrosine kinase inhibitor that was approved by FDA on April 29, 2014, as a medication for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
Earlier this year, IMS Health released a report indicating that overall drug spend in the United States increased by 3.2% in 2013.1 That increase stands in contrast to the 1% decline in drug spend in 2012.1 IMS noted that primary drivers of the increase include fewer patent expirations, drug price increases, expensive new drug therapies, and greater use of the healthcare system. Considering these drivers, all indications are that drug spend will continue to increase in the years to come.
The federal government’s cost for Medicare Part D will increase between $2.9 billion and $5.8 billion if we see 15% to 30% of hepatitis C (HCV)-infected beneficiaries receive treatment in 2015 and the cost of treatment averages $84,000, according to a new study by Milliman.
ADA: Canagliflozin may be cost-effective treatment option for type 2 diabetes with diet, exercise: Studies
In adult patients with type 2 diabetes inadequately controlled on metformin monotherapy—the current standard of treatment— canagliflozin (Invokana) 100 mg and 300 mg reduced relative risk for myocardial infarction (1.6% and 3.0%) and congestive heart failure (2.7% and 4.0%), as compared to sitagliptin 100 mg, according to findings of the health economic simulation analysis presented at the American Diabetes Association (ADA) Scientific Sessions in San Francisco.